Yaniv Sadka

Terrarium is a venture studio by Company Ventures building the next wave of transformational health tech startups. The studio incubates companies from -1 to 0 by bringing together exceptional founders, unique insights, capital, and long standing industry relationships.

Company Ventures is a NYC-based venture capital firm that invests in new technology-driven businesses at the earliest stages. We predominantly invest in digital health, fintech and enterprise SaaS businesses at pre-seed, seed and series A stages through our funds with a typical check size of ~$500k-$1M.

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.

Terrarium is a venture studio by Company Ventures building the next wave of transformational health tech startups. The studio incubates companies from -1 to 0 by bringing together exceptional founders, unique insights, capital, and long standing industry relationships.

Company Ventures is a NYC-based venture capital firm that invests in new technology-driven businesses at the earliest stages. We predominantly invest in digital health, fintech and enterprise SaaS businesses at pre-seed, seed and series A stages through our funds with a typical check size of ~$500k-$1M.

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.

Deloitte drives progress. Our firms around the world help clients become leaders wherever they choose to compete. Deloitte invests in outstanding people of diverse talents and backgrounds and empowers them to achieve more than they could elsewhere. Our work combines advice with action and integrity. We believe that when our clients and society are stronger, so are we. Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities. DTTL (also referred to as “Deloitte Global”) and each of its member firms are legally separate and independent entities. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more. The content on this page contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on content from this page.

Cedars-Sinai Accelerator+ represents the evolution of our proven accelerator model into a comprehensive venture-building platform for Seed+ / Late Seed healthcare companies advancing towards commercialization. We partner directly with startup teams, providing capital investment, clinical and market expertise, and guaranteed fast-track evaluation for product development within the Cedars-Sinai Health System and beyond, thereby providing qualified connections into a national network of academic medical centers who are looking to implement new solutions in their institutions. Our 12-month program delivers real-world validation, streamlines clinical integration, and provides strategic guidance to scale innovation and improve patient outcomes.